Back to Search Start Over

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review

Authors :
Siti Muhamad Nur Husna
Hern-Tze Tina Tan
Rohimah Mohamud
Anne Dyhl-Polk
Kah Keng Wong
Source :
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Publication Year :
2018
Publisher :
SAGE Publishing, 2018.

Abstract

Breast cancer is the global leading cause of cancer-related death in women and it represents a major health burden worldwide. One of the promising breast cancer therapeutic avenues is through small molecule inhibitors (SMIs) which have undergone rapid progress with successful clinical trials. Recently, three emerging and vital groups of proteins are targeted by SMIs for breast cancer treatment, namely cyclin-dependent kinase 4 and 6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP) and phosphoinositide 3-kinase (PI3K). Several of these inhibitors have been approved for the treatment of breast cancer patients or progressed into late-stage clinical trials. Thus, modeling from these successful clinical trials, as well as their limitations, is pivotal for future development and trials of other inhibitors or therapeutic regimens targeting breast cancer patients. In this review, we discuss eight recently approved or novel SMIs against CDK4/6 (palbociclib, ribociclib and abemaciclib), PARP (olaparib, veliparib and talazoparib), and PI3K (buparlisib and alpelisib). The mechanisms of action, series of clinical trials and limitations are described for each inhibitor.

Details

Language :
English
ISSN :
17588359
Volume :
10
Database :
Directory of Open Access Journals
Journal :
Therapeutic Advances in Medical Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.80cba12890ed4689a23828add3650b83
Document Type :
article
Full Text :
https://doi.org/10.1177/1758835918808509